Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial. Issue 12 (28th October 2020)

• Record Type: Journal Article
• Authors: Fukano, Reiji; Mori, Tetsuya; Sekimizu, Masahiro; Choi, Ilseung; Kada, Akiko; Saito, Akiko Moriya; Asada, Ryuta; Takeuchi, Kengo; Terauchi, Takashi; Tateishi, Ukihide; Horibe, Keizo; Nagai, Hirokazu
• Is Part Of: Cancer science. Volume 111:Issue 12(2020)
• Page Start: 4540
• Page End: 4547
• Publication Date: 2020-10-28
• Subjects: alectinib -- ALK inhibitor -- anaplastic large cell lymphoma -- refractory -- relapse; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14671
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Anaplastic lymphoma kinase (ALK) inhibition is expected to be a promising therapeutic strategy for ALK‐positive malignancies. We aimed to examine the efficacy and safety of alectinib, a second‐generation ALK inhibitor, in patients with relapsed or refractory ALK‐positive anaplastic large cell lymphoma (ALCL). This open‐label, phase II trial included patients (aged 6 years or older) with relapsed or refractory ALK‐positive ALCL. Alectinib 300 mg was given orally twice a day (600 mg/d) for 16 cycles, and the duration of each cycle was 21 days. Patients who weighed less than 35 kg were given a reduced dose of alectinib of 150 mg twice a day (300 mg/d). Ten patients were enrolled, and the median age was 19.5 years (range, 6‐70 years). Objective responses were documented in eight of 10 patients (80%; 90% confidence interval, 56.2‐95.9), with six complete responses. The 1‐year progression‐free survival, event‐free survival, and overall survival rates were 58.3%, 70.0%, and 70.0%, respectively. The median duration of therapy was 340 days. No unexpected adverse events occurred. The most common grade 3 and higher adverse event was a decrease in neutrophil count in two patients. Alectinib showed favorable clinical activity and was well tolerated in patients with ALK‐positive ALCL who had progressed on standard chemotherapy. Based on the results of the current study, the Ministry of Health, Labour and Welfare of Japan approved alectinib for the treatment of recurrent or refractory ALK‐positive ALCL in February 2020. Abstract : This phase II study aimed to assess the efficacy and safety of alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, in patients with relapsed or refractory ALK‐positive anaplastic large cell lymphoma (ALCL). Alectinib showed favorable clinical activity, was well tolerated, and represents a good treatment option for pediatric or adult patients. Based on the results of this study, the Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare in Japan has approved alectinib for the treatment of recurrent or refractory ALK‐positive ALCL.